LUNG vs TCMD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

LUNG

32.6
AI Score
VS
LUNG Wins

TCMD

23.1
AI Score

Investment Advisor Scores

LUNG

33score
Recommendation
SELL

TCMD

23score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LUNG TCMD Winner
Revenue 66.18M 252.82M TCMD
Net Income -32.13M 13.18M TCMD
Gross Margin 77.3% 76.5% LUNG
Net Margin -48.5% 5.2% TCMD
Operating Income -29.50M 14.88M TCMD
ROE -93.9% 5.8% TCMD
ROA -29.2% 4.5% TCMD
Total Assets 110.21M 291.29M TCMD
Cash 52.69M 75.11M TCMD
Current Ratio 4.05 3.51 LUNG
Free Cash Flow -18.51M 12.24M TCMD

Relative Price Performance (Last 90 Days)

LUNG 1M: +55.6% · 3M: +22.3% TCMD 1M: +17.7% · 3M: +8.6%

Current Technical Phase

LUNG

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 62

RSI (14): 62.5 · Price: $2.80

TCMD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 65.5 · Price: $26.62

Fundamentals Snapshot

Metric LUNG TCMD
Market Cap — —
Forward P/E -3.1 18.1
Trailing P/E — 25.8
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.8% 0.8%
Operating Margin -0.3% 0.1%
EPS -1.01 1.03
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, LUNG is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.